BeOne Medicines AG (ONC)
Thursday, November 5, 2026
Key stats
Chart
Price, buy and sell signals and key levels on one chart.
Past 1Y
MA21MA180
SignalsBuyEarly buySellEarly sellTurning pointsSwing highSwing low
Up dayDown day
Thursday, November 5, 2026
Price, buy and sell signals and key levels on one chart.
BeOne Medicines (ONC) closed at $361.27 on Nov 2, 2026, down 2.4% on the day. The stock is up 0.9% over the past month, up 11.8% over three months, up 18.9% year to date and up 16.4% over the past year (since Oct 31, 2025). It trades 7.0% below its 52-week high of $388.66 and 42.3% above its 52-week low of $253.95. The close sits below its 50-day moving average ($362.88) and above its 200-day moving average ($325.02).
ONC is scheduled to report earnings on Nov 5, 2026, before market open.
BeOne Medicines is scheduled to report on Nov 5, 2026, before market open.
Yes — the Nov 2, 2026 close of $361.27 is 11.2% above the 200-day average of $325.02.
ONC closed 7.0% below its 52-week high of $388.66.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.